NCT06861855Not yet recruiting
Prognosis of METTL-14 in Endometrial Carcinoma
Prognostic Impact of Immunohistochemical Expression of METTL-14 in Endometrial Carcinoma
Source: ClinicalTrials.gov · Last updated 30 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. To evaluate immunohistochemical expression of METTL14 in type1 endometrial carcinoma. 2. To evaluate the correlation between METTL14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection. 3. To assess correlation of METTL-14 expression with disease free survival and overall survival.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 22 Feb 2025
- Start date
- 27 Sept 2025
- Primary completion date
- Aug 2026
- Lead sponsor
- Assiut University
- Diseases
- Endometrial cancer, Childhood cancers
- NCT number
- NCT06861855
What you commit to
- Study type: Observational
- Planned participants: 50
- From 27 Sept 2025 to the primary completion date, Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Any case of type 1 endometrial carcinoma with missing clinical, radiologic or follow up data.
- 2\. Cases with no available H\&E stained slides or formalin fixed paraffin embedded block.
- 3.D\&C.
Who the study is looking for
- Cases of type1endometrial carcinoma with:
- Hystrectomy operation
- Available full clinical data about patient (age, complaint, findings in clinical examination).
- Full data about previous biopsy and radiology.
- Full data about patient survival, disease progression and history of chemotherapy for three years.
Sex: Female
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| AssuitU Coordinator of this site? Confirm its status | Asyut | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.